Access to anti-retroviral drugs, male in Cameroon

Cameroon: Access to anti-retroviral drugs, male was 79.0% in 2024. ◆ Volatile

Latest (2024)
79.0%
Change on year
up 3.9%
World rank
49th
of 141 countries
All-time high
79.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, male in Cameroon, 2000–2024

0204060802000201220242000: 0 %2001: 0 %2002: 0 %2003: 0 %2004: 3 %2005: 5 %2006: 5 %2007: 9 %2008: 11 %2009: 14 %2010: 16 %2011: 19 %2012: 16 %2013: 17 %2014: 19 %2015: 22 %2016: 28 %2017: 35 %2018: 41 %2019: 47 %2020: 54 %2021: 62 %2022: 70 %2023: 76 %2024: 79 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2024, access to anti-retroviral drugs, male in Cameroon stood at 79.0%. That is the highest value across all 25 years on record.

The figure is up 3.9% on the previous year and up 315.8% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Cameroon peaked at 79.0% in 2024 and was at its lowest, 0.0%, in 2000.

Cameroon ranks 49th of 141 countries on this measure, in the middle of the range.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, male in Cameroon, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Cameroon, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 0.0%
2004 3.0%
2005 5.0% +66.7%
2006 5.0% +0.0%
2007 9.0% +80.0%
2008 11.0% +22.2%
2009 14.0% +27.3%
2010 16.0% +14.3%
2011 19.0% +18.8%
2012 16.0% -15.8%
2013 17.0% +6.2%
2014 19.0% +11.8%
2015 22.0% +15.8%
2016 28.0% +27.3%
2017 35.0% +25.0%
2018 41.0% +17.1%
2019 47.0% +14.6%
2020 54.0% +14.9%
2021 62.0% +14.8%
2022 70.0% +12.9%
2023 76.0% +8.6%
2024 79.0% +3.9%

Averages by decade

DecadeAverage LowestHighest Years
2000s 4.7% 0.0% 14.0% 10
2010s 26.0% 16.0% 47.0% 10
2020s 68.2% 54.0% 79.0% 5

Countries ranked near Cameroon

  1. 46 Uganda 81.0% compare
  2. 47 Azerbaijan 80.0% compare
  3. 47 Lebanon 80.0% compare
  4. 49 Peru 79.0% compare
  5. 51 Benin 78.0% compare
  6. 51 Canada 78.0% compare
  7. 51 El Salvador 78.0% compare

See the full ranking of 160 places →

More gender data for Cameroon

All data for Cameroon →

Frequently asked questions

What is access to anti-retroviral drugs, male in Cameroon?
Access to anti-retroviral drugs, male in Cameroon was 79.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Cameroon?
The highest recorded value was 79.0% in 2024.
What is the lowest access to anti-retroviral drugs, male recorded in Cameroon?
The lowest recorded value was 0.0% in 2000.
How does Cameroon rank for access to anti-retroviral drugs, male?
Cameroon ranks 49th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, male rising or falling in Cameroon?
Over the last ten years it is up 315.8%. The long-run trend across the full record is volatile.
Where does this Cameroon data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Cameroon. Statizoid, drawing on UNAIDS estimates. Retrieved 09 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/cameroon/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/cameroon/">Access to anti-retroviral drugs, male in Cameroon</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.